Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at UT Southwestern Medical Center, shared a post on X:
“CIRCUIT trial: single arm Ph2 (n=41).
RT (22.5Gy/5fx) + nivo in heavily pretreated advanced gastric ca – high local control (85% 1 yr, median 50 mo).
Even in a systemically driven disease, low-dose palliative RT can offer durable control? Act as an immune primer.”
Title: Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes
Authors: Yoshiyuki Suzuki, Daisaku Yoshida, Kosaku Mimura, Takashi Ogata, Yuya Yoshimoto, Hiroyuki Katoh, Hiroyuki Hanayama, Nozomu Machida, Hisashi Sato, Zenichiro Saze, Takanobu Yamada, Yasuhiro Inokuchi, Fumiaki Takahashi, Takashi Oshima, Koji Kono
Read The Full Article
Other articles about Radiotherapy on OncoDaily.